Cholesterol Biosynthesis: How Your Body Produces Cholesterol

Your body manufactures the majority of its own cholesterol through an intricate, multi-step assembly line that runs in nearly every cell, with the liver doing the heaviest lifting. This internal production dwarfs what you absorb from food, which is one reason dietary cholesterol has a smaller effect on blood levels than most people assume. The pathway that builds cholesterol from scratch involves more than 20 chemical reactions, tightly controlled by feedback sensors that can ramp production up or down depending on the cell’s needs. Understanding how this system works explains a lot about why cholesterol-related health problems develop and how medications intervene.

Why Your Body Bothers Making Cholesterol at All

Cholesterol has a reputation as something to minimize, but your cells genuinely need it. Its main job is maintaining the structure and fluidity of cell membranes, the thin barriers that surround every cell and many of the compartments inside them.¹ Without enough cholesterol packed into those membranes, cells become either too rigid or too leaky, disrupting everything from nutrient uptake to signaling between cells.

Beyond structural duty, cholesterol serves as the raw material for several molecules you cannot live without. Your adrenal glands and gonads convert it into steroid hormones like cortisol, testosterone, and estrogen. Your liver uses it to make bile acids, which you need to digest and absorb dietary fats. And your skin uses a cholesterol derivative to synthesize vitamin D when exposed to sunlight.¹ Because these functions are so essential, evolution built the body to produce cholesterol internally rather than rely entirely on diet.

The Starting Material and the Rate-Limiting Step

Cholesterol synthesis begins with acetyl coenzyme A, a small molecule your cells generate constantly from the breakdown of fats, sugars, and proteins. Through a series of more than 20 reactions, that simple two-carbon building block gets lengthened, rearranged, and ultimately folded into the four-ring sterol structure of cholesterol.² The whole process happens on membranes inside cells, primarily in a compartment called the endoplasmic reticulum.

The single most important step in the pathway is the conversion of a molecule called HMG-CoA into mevalonate. The enzyme responsible, HMG-CoA reductase, is considered the rate-limiting enzyme of cholesterol synthesis, meaning it controls how fast or slow the entire pathway runs.³ If you think of cholesterol production as an assembly line, HMG-CoA reductase is the bottleneck station. Speed it up and more cholesterol gets made; slow it down and production drops. This is exactly why statins, the most widely prescribed cholesterol-lowering drugs, were designed to block this particular enzyme.⁴

From Mevalonate to Squalene to Cholesterol

Once mevalonate is formed, the pathway enters what researchers call the pre-squalene segment. Mevalonate gets phosphorylated and then converted through several steps into small building blocks that snap together to form progressively longer carbon chains. The key intermediates along the way are molecules like isopentenyl pyrophosphate, geranyl pyrophosphate, and farnesyl pyrophosphate. Two farnesyl pyrophosphate molecules then join head to head to form squalene, a 30-carbon chain that is the direct precursor to the sterol ring system.⁵

After squalene forms, the molecule gets cyclized into lanosterol, which is the first compound in the pathway that actually looks like a sterol. From lanosterol to the final product, cholesterol, there are roughly another dozen reactions that strip away extra methyl groups, shift double bonds, and reduce the side chain. Researchers have identified two classical routes through this post-lanosterol stretch, and studies using labeled intermediates in living cells show that many tissues actually use a hybrid of both, switching between them partway through.⁶ The details of which route a cell favors can vary by tissue type, which matters for understanding certain genetic diseases where one of these late-stage enzymes is defective.

How Cells Know When to Make More or Less

Cells do not just churn out cholesterol blindly. They use a remarkably sensitive feedback system anchored in the endoplasmic reticulum, the very membrane where cholesterol is synthesized. Despite being the production site, the endoplasmic reticulum keeps its own cholesterol content quite low, around three to six percent of its total lipids.⁷ That low baseline is deliberate, because the regulatory machinery sitting in those membranes is exquisitely tuned to detect even small changes in cholesterol concentration.

The master switch is a protein called SREBP-2, which sits embedded in the endoplasmic reticulum membrane. When cholesterol levels in the membrane are adequate, a sensor protein called Scap binds cholesterol and stays anchored in the endoplasmic reticulum by interacting with another protein called Insig. This keeps SREBP-2 locked in place and inactive.⁸ But when cholesterol drops below a threshold of roughly five percent of endoplasmic reticulum lipids, Scap releases from Insig, escorts SREBP-2 to another cellular compartment where it gets clipped, and the freed fragment travels to the nucleus to switch on genes for cholesterol-making enzymes.⁹ The transition from “off” to “on” is remarkably abrupt, behaving almost like a binary switch rather than a gradual dial.

On top of this transcriptional control, cells also regulate HMG-CoA reductase directly after it has been made. An energy-sensing enzyme called AMP-activated protein kinase can tag HMG-CoA reductase with a phosphate group, which inactivates it.¹⁰ This means that when a cell is low on energy, it effectively shuts down cholesterol production to conserve resources. The system is layered: one set of controls decides how much enzyme to make, and another set decides how active the existing enzyme should be.

Cholesterol Production Follows a Clock

Cholesterol synthesis is not constant throughout the day. It follows a circadian rhythm, with production peaking during the night and dropping to its lowest point in the afternoon. Animal studies first demonstrated this pattern by measuring HMG-CoA reductase activity across the day-night cycle, finding that hepatic cholesterol synthesis rates at the nighttime peak were substantially higher than at the midday nadir.¹¹ Human studies confirm a similar pattern by tracking blood levels of lathosterol, a cholesterol precursor that serves as a marker of how actively synthesis is running. Lathosterol peaks nocturnally and bottoms out in the afternoon.¹²

This rhythm is the reason early short-acting statins were originally recommended for evening dosing. Taking the drug at bedtime meant it hit peak blood levels just as the liver’s cholesterol-making machinery was revving up. Longer-acting statins used today stay in the system long enough to cover the entire cycle, making the timing of the dose less critical. Still, the underlying circadian biology has not changed, and it illustrates that cholesterol metabolism is not a static background process but an active, timed one.

Where in the Body Synthesis Happens

The liver is by far the largest contributor to the cholesterol that circulates in your blood. After making cholesterol, liver cells package it into lipoproteins, primarily VLDL particles, which transport cholesterol and fats into the bloodstream.¹³ As VLDL particles travel through the circulation, enzymes strip away their fat content, and roughly half of what remains gets taken back up by the liver. The other half becomes LDL, the particle most commonly associated with cardiovascular risk, which delivers cholesterol to cells throughout the body.¹⁴

But the liver is not the only site. Nearly every nucleated cell in your body can synthesize cholesterol, and some tissues are especially active. The brain is a striking example. Because blood-borne lipoproteins cannot cross the blood-brain barrier, almost all cholesterol in the brain is made locally by brain cells themselves.¹⁵ The brain contains roughly a quarter of the body’s total cholesterol despite making up only about two percent of body weight. This local self-sufficiency means brain cholesterol metabolism is largely independent of what is happening in the bloodstream, which is one reason cholesterol-lowering medications have complicated and still-debated relationships with neurological outcomes.

Why Dietary Cholesterol Has a Smaller Effect Than You Might Expect

Given how much cholesterol the body produces internally, the contribution from food is relatively modest. Cholesterol balance is maintained through a combination of internal synthesis and intestinal absorption, and these two systems are linked by feedback.¹⁶ However, the feedback control exerted by dietary cholesterol on synthesis is weaker than you might expect. One reason is that the intestinal absorption mechanism is already close to saturation from the large amounts of cholesterol the body secretes into the gut through bile and then reabsorbs. Dietary cholesterol adds to a pool that is already largely maxed out.¹⁷

This does not mean diet is irrelevant, but it reframes the picture. The internal production system is the dominant player, and interventions aimed at lowering blood cholesterol focus overwhelmingly on altering that internal machinery rather than restricting dietary intake. Saturated fat, for instance, affects blood cholesterol not primarily by delivering cholesterol to the body but by influencing the liver’s handling of LDL particles.

What Happens When the Pathway Breaks

Several rare genetic disorders demonstrate just how critical the cholesterol synthesis pathway is. The best-studied is Smith-Lemli-Opitz syndrome, caused by a defect in the enzyme that catalyzes the very last step of the pathway, the conversion of 7-dehydrocholesterol to cholesterol. Children born with this condition produce insufficient cholesterol, and the precursor molecule that should have been converted into cholesterol accumulates instead.¹⁸

The consequences are severe and wide-ranging. Over 95 percent of affected patients have fused second and third toes, and many have additional limb and craniofacial abnormalities, organ malformations affecting the brain and heart, and intellectual disability.¹⁹ Many of the developmental abnormalities in this and related syndromes affect structures that depend on Hedgehog signaling during embryonic development, a signaling pathway that requires cholesterol to function properly.²⁰ Several other rare syndromes have been traced to defects at other points in the cholesterol synthesis pathway, and all share the common feature of both cholesterol deficiency and accumulation of potentially toxic precursor sterols.²¹

Drugs That Target the Pathway

Statins remain the most familiar drugs targeting cholesterol biosynthesis. They work as competitive inhibitors of HMG-CoA reductase, blocking the rate-limiting step and forcing the liver to pull more LDL cholesterol out of the blood to compensate for the drop in internal production.²² The compensatory upregulation of LDL receptors on liver cells is actually the primary mechanism by which statins lower blood LDL levels.

A newer drug, bempedoic acid, targets the pathway even further upstream. Instead of blocking HMG-CoA reductase directly, it inhibits ATP-citrate lyase, an enzyme that generates the acetyl-CoA the pathway needs as its starting material.²³ By starving the pathway of substrate rather than blocking a downstream enzyme, bempedoic acid triggers a similar compensatory increase in LDL receptor activity. In lab experiments, reducing ATP-citrate lyase protein by about 80 percent led to more than a 50 percent increase in LDL receptor protein and a fourfold increase in receptor activity.²⁴ A practical advantage of bempedoic acid is that it is only activated in the liver, which may explain why it causes fewer muscle-related side effects than statins, since it does not interfere with cholesterol synthesis in muscle tissue.

An Ancient Pathway Shared Across Life

The cholesterol biosynthesis pathway is not a recent evolutionary invention. Phylogenetic analyses indicate that the last common ancestor of all eukaryotes already possessed a large panel of sterol synthesis enzymes, and subsequent evolution proceeded mainly through losses rather than gains of new genes.²⁵ In animals specifically, the enzymes of the cholesterol pathway show strong conservation across virtually all classes of eukaryotes, and reconstructed evolutionary trees suggest most of these genes were inherited vertically from the closest single-celled relatives of animals rather than acquired by horizontal transfer.²⁶

This deep conservation tells us something about how fundamental sterols are to eukaryotic life. Plants make phytosterols, fungi make ergosterol, and animals make cholesterol, but they all use recognizably related enzymatic machinery to do it. Insects are a notable exception: they lost the ability to synthesize sterols and must obtain them from their diet, which is why certain insecticides target sterol metabolism. The fact that nearly all other eukaryotic lineages have held on to this pathway for over a billion years underscores how indispensable cholesterol and its relatives are to membrane function and cellular signaling.

Cholesterol Synthesis Beyond Membranes and Hormones

Research continues to uncover roles for cholesterol synthesis that go beyond the familiar textbook functions. One recent area involves blood stem cells. Work on hematopoietic stem cells has shown that fatty acid breakdown generates the cellular fuel needed to power cholesterol synthesis in those cells, and stem cells with higher cholesterol levels behave differently from those with lower levels.²⁷ The connection between a cell’s energy state and its cholesterol production appears to influence whether stem cells remain dormant or activate, hinting that cholesterol biosynthesis serves as a kind of metabolic signal in addition to its structural role.

The discovery of this pathway in 1942 by Konrad Bloch and David Rittenberg, who showed that labeled acetate was incorporated into the cholesterol ring structure, launched decades of biochemical detective work.²⁸ The field has moved from mapping individual reactions to understanding the pathway as an integrated system embedded in broader cellular metabolism. Each year, new connections emerge between cholesterol synthesis and processes like immune signaling, cell division, and tissue development, reinforcing that this ancient molecular assembly line is far more than a supplier of membrane filler.